Elite in Relapsing Polychondritis

Zahir Amoura

Paris, FR 
Elite in Relapsing Polychondritis
Paris, FR 
OverviewLocationsClinical Research

Overview

Zahir Amoura practices in Paris, France. Mr. Amoura is rated as an Elite expert by MediFind in the treatment of Relapsing Polychondritis. His top areas of expertise are Erdheim-Chester Disease, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Heart Transplant.

His clinical research consists of co-authoring 464 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Relapsing Polychondritis.

Gender
Male

Locations

Paris, France
Other Locations
Hospices Civils de Lyon
Lyon, France
Université Paris Est Créteil, Creteil, France
Ste Blandine Hospital, Nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment
Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment
Enrollment Status: Terminated
Publish Date: March 25, 2022
Intervention Type: Biological
Study Drug: Autologous EBV specific CTL infusion
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

464 Total Publications

Cutaneous Vasculitis in Primary Sjögren Disease.
Cutaneous Vasculitis in Primary Sjögren Disease.
Journal: JAMA dermatology
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Amoura's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 10 Distinguished Conditions
View All 27 Advanced Conditions
View All 100 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile